Therapeutic doses of MLN2704 can be administered safely on a repetitive basis. An MTD was not defined. MLN2704 is being administered at more frequent intervals in ongoing trials to determine an optimal dosing schedule.
Also Known As:
MLN2704 antibody, human
relevant articles (0 outcomes,
Bio-Agent Context: Research Results